SUPPLEMENTARY DATA

Nilotinib Improves Bioenergetic Profiling in Brain Astroglia in the 3xTg Mouse Model of Alzheimer's Disease

Aida Adlimoghaddam[1,*], Gary G. Odero[1], Gordon Glazner[1,2], R. Scott Turner[3], Benedict C. Albensi[1,2,*]

SUPPLEMENTARY DATA



Supplementary Figure 1. Characterization of culture purity. Both immunohistochemistry **(A)** and immunofluorescence **(B)** were utilized to detect astrocytes. Purity of cell culture was determined via immunofluorescence using markers specific for detecting astrocytes (GFAP) and microglia (Iba-1). Red arrows indicate the astrocytes. Nuclei were labeled blue with DAPI. The percentages of astrocytes and microglia were determined. Results are expressed as mean ± SD of n = 5 (**** = $p < 0.0001$).

SUPPLEMENTARY DATA



Supplementary Figure 2. Nilotinib did not alter the activity of citrate synthase (n = 6/group) in C57BL/6-WT and 3xTg-AD astroglia. Specific enzyme activity of citrate synthase was measured in C57BL/6-WT **(A)** and 3xTg-AD **(B)** astroglia in presence and absence of 100 nM nilotinib treatment. Results are expressed as mean ± SD of n = 6 per group (*P ≤ 0.05) analyzed by unpaired Student's t-test.